Difference between revisions of "Bavituximab (PGN-401)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Immunotherapy" to "Category:Immunotherapeutic") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
||
| Line 15: | Line 15: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Revision as of 18:05, 3 February 2019
Mechanism of action
Binds to phosphatidylserine, provoking an immune response.
Preliminary data
Non-small cell lung cancer
- Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. link to original article PubMed